Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | decreases expression | ISO | RGD:1331928 | 6480464 | ethylene dichloride results in decreased expression of LPHN2 mRNA | CTD | PMID:28960355 | 17beta-estradiol | multiple interactions | ISO | RGD:732054 | 6480464 | [Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA | CTD | PMID:20660070 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:732054 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ADGRL2 mRNA | CTD | PMID:20106945, PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1331928 | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADGRL2 mRNA | CTD | PMID:25975270 | 2,4-diaminotoluene | decreases expression | ISO | RGD:1331928 | 6480464 | 2, 4-diaminotoluene results in decreased expression of ADGRL2 mRNA | CTD | PMID:20713471 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2, 4-dinitrotoluene affects the expression of ADGRL2 mRNA | CTD | PMID:21346803 | 3,4-methylenedioxymethamphetamine | decreases expression | EXP | | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of ADGRL2 mRNA | CTD | PMID:30071829 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | 3H-1,2-dithiole-3-thione | decreases expression | EXP | | 6480464 | 1, 2-dithiol-3-thione results in decreased expression of ADGRL2 mRNA | CTD | PMID:19162173 | 4,4'-diaminodiphenylmethane | decreases expression | EXP | | 6480464 | 4, 4'-diaminodiphenylmethane results in decreased expression of ADGRL2 mRNA | CTD | PMID:30723492 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1331928 | 6480464 | Fenretinide results in increased expression of ADGRL2 mRNA | CTD | PMID:28973697 | 5-fluorouracil | affects response to substance | ISO | RGD:732054 | 6480464 | ADGRL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:16217747 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of ADGRL2 mRNA | CTD | PMID:24780913, PMID:25825206 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of ADGRL2 mRNA | CTD | PMID:31881176 | aflatoxin B1 | decreases expression | ISO | RGD:1331928 | 6480464 | Aflatoxin B1 results in decreased expression of ADGRL2 mRNA | CTD | PMID:19770486 | aflatoxin B1 | increases methylation | ISO | RGD:732054 | 6480464 | Aflatoxin B1 results in increased methylation of ADGRL2 intron | CTD | PMID:30157460 | arsenite(3-) | decreases expression | ISO | RGD:732054 | 6480464 | arsenite results in decreased expression of ADGRL2 mRNA | CTD | PMID:23974009 | benzo[a]pyrene | decreases expression | ISO | RGD:1331928 | 6480464 | Benzoapyrene results in decreased expression of ADGRL2 mRNA | CTD | PMID:19770486 | benzo[a]pyrene | decreases methylation | ISO | RGD:732054 | 6480464 | Benzoapyrene results in decreased methylation of LPHN2 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | increases methylation | ISO | RGD:732054 | 6480464 | Benzoapyrene results in increased methylation of LPHN2 promoter | CTD | PMID:27901495 | benzo[a]pyrene | increases expression | ISO | RGD:1331928 | 6480464 | Benzoapyrene results in increased expression of ADGRL2 mRNA | CTD | PMID:22610609 | benzo[b]fluoranthene | increases expression | ISO | RGD:1331928 | 6480464 | benzobfluoranthene results in increased expression of ADGRL2 mRNA | CTD | PMID:26377693 | beta-naphthoflavone | multiple interactions | ISO | RGD:1331928 | 6480464 | AHR protein affects the reaction [beta-Naphthoflavone results in decreased expression of ADGRL2 mRNA] | CTD | PMID:22234961 | beta-naphthoflavone | decreases expression | ISO | RGD:1331928 | 6480464 | beta-Naphthoflavone results in decreased expression of ADGRL2 mRNA | CTD | PMID:22234961 | bis(2-chloroethyl) sulfide | affects expression | EXP | | 6480464 | Mustard Gas affects the expression of ADGRL2 mRNA | CTD | PMID:15651846 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of ADGRL2 mRNA | CTD | PMID:12075121, PMID:30816183 | bisphenol A | increases expression | ISO | RGD:732054 | 6480464 | bisphenol A results in increased expression of ADGRL2 mRNA | CTD | PMID:29275510 | bisphenol A | decreases methylation | ISO | RGD:1331928 | 6480464 | bisphenol A results in decreased methylation of ADGRL2 promoter | CTD | PMID:27312807 | bisphenol A | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of ADGRL2 mRNA | CTD | PMID:25181051 | butanal | decreases expression | ISO | RGD:732054 | 6480464 | butyraldehyde results in decreased expression of ADGRL2 mRNA | CTD | PMID:26079696 | calcium atom | multiple interactions | EXP | | 6480464 | [alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium, [black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium | CTD | PMID:10026162 | calcium(0) | multiple interactions | EXP | | 6480464 | [alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium, [black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium | CTD | PMID:10026162 | choline | multiple interactions | ISO | RGD:1331928 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL2 | CTD | PMID:20938992 | chromium atom | decreases expression | ISO | RGD:732054 | 6480464 | Chromium results in decreased expression of ADGRL2 mRNA | CTD | PMID:21437242 | copper atom | multiple interactions | ISO | RGD:1331928 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA | CTD | PMID:15467011 | copper(0) | multiple interactions | ISO | RGD:1331928 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of ADGRL2 mRNA | CTD | PMID:15467011 | cyclosporin A | decreases expression | ISO | RGD:732054 | 6480464 | Cyclosporine results in decreased expression of ADGRL2 mRNA | CTD | PMID:20106945, PMID:25562108 | dexamethasone | decreases expression | EXP | | 6480464 | Dexamethasone results in decreased expression of ADGRL2 mRNA | CTD | PMID:14618091 | dexamethasone | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of ADGRL2 mRNA | CTD | PMID:21266533 | dibutyl phthalate | increases expression | ISO | RGD:1331928 | 6480464 | Dibutyl Phthalate results in increased expression of ADGRL2 mRNA | CTD | PMID:17361019, PMID:21266533 | dorsomorphin | multiple interactions | ISO | RGD:732054 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:732054 | 6480464 | Doxorubicin results in decreased expression of ADGRL2 mRNA | CTD | PMID:29803840 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of ADGRL2 mRNA | CTD | PMID:29391264 | ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of ADGRL2 mRNA | CTD | PMID:15353170 | ethanol | increases expression | ISO | RGD:1331928 | 6480464 | Ethanol results in increased expression of ADGRL2 mRNA | CTD | PMID:30319688 | flusilazole | affects expression | ISO | RGD:1331928 | 6480464 | flusilazole affects the expression of ADGRL2 mRNA | CTD | PMID:21195148 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of ADGRL2 mRNA | CTD | PMID:24136188, PMID:24793618 | folic acid | multiple interactions | ISO | RGD:1331928 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL2 | CTD | PMID:20938992 | fonofos | increases methylation | ISO | RGD:732054 | 6480464 | Fonofos results in increased methylation of ADGRL2 promoter | CTD | PMID:22847954 | furan | increases methylation | EXP | | 6480464 | furan results in increased methylation of ADGRL2 gene | CTD | PMID:22079235 | hexaconazole | affects expression | ISO | RGD:1331928 | 6480464 | hexaconazole affects the expression of ADGRL2 mRNA | CTD | PMID:21195148 | indometacin | multiple interactions | ISO | RGD:732054 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADGRL2 mRNA | CTD | PMID:28628672 | L-methionine | multiple interactions | ISO | RGD:1331928 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ADGRL2 gene, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ADGRL2 | CTD | PMID:20938992 | methapyrilene | decreases expression | EXP | | 6480464 | Methapyrilene results in decreased expression of ADGRL2 mRNA | CTD | PMID:30467583 | methotrexate | affects response to substance | ISO | RGD:732054 | 6480464 | ADGRL2 protein affects the susceptibility to Methotrexate | CTD | PMID:16217747 | nefazodone | decreases expression | EXP | | 6480464 | nefazodone results in decreased expression of ADGRL2 mRNA | CTD | PMID:24136188 | nimesulide | decreases expression | EXP | | 6480464 | nimesulide results in decreased expression of ADGRL2 mRNA | CTD | PMID:24136188 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of ADGRL2 mRNA | CTD | PMID:25729387 | paracetamol | affects expression | ISO | RGD:1331928 | 6480464 | Acetaminophen affects the expression of ADGRL2 mRNA | CTD | PMID:17562736 | paracetamol | decreases expression | ISO | RGD:732054 | 6480464 | Acetaminophen results in decreased expression of ADGRL2 mRNA | CTD | PMID:21420995 | parathion | increases methylation | ISO | RGD:732054 | 6480464 | Parathion results in increased methylation of ADGRL2 promoter | CTD | PMID:22847954 | pirinixic acid | multiple interactions | ISO | RGD:1331928 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of ADGRL2 mRNA | CTD | PMID:19710929 | pirinixic acid | decreases expression | EXP | | 6480464 | pirinixic acid results in decreased expression of ADGRL2 mRNA | CTD | PMID:19162173 | potassium chromate | decreases expression | ISO | RGD:732054 | 6480464 | potassium chromateVI results in decreased expression of ADGRL2 mRNA | CTD | PMID:22714537 | progesterone | multiple interactions | ISO | RGD:732054 | 6480464 | [Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA | CTD | PMID:20660070 | quercetin | decreases expression | ISO | RGD:732054 | 6480464 | Quercetin results in decreased expression of ADGRL2 mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | RGD:732054 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | sunitinib | increases expression | ISO | RGD:732054 | 6480464 | Sunitinib results in increased expression of ADGRL2 mRNA | CTD | PMID:31533062 | terbufos | increases methylation | ISO | RGD:732054 | 6480464 | terbufos results in increased methylation of ADGRL2 promoter | CTD | PMID:22847954 | titanium dioxide | decreases expression | EXP | | 6480464 | titanium dioxide results in decreased expression of ADGRL2 mRNA | CTD | PMID:30012374 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of ADGRL2 mRNA | CTD | PMID:25729387 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of ADGRL2 mRNA | CTD | PMID:25729387 | triadimefon | affects expression | ISO | RGD:1331928 | 6480464 | triadimefon affects the expression of ADGRL2 mRNA | CTD | PMID:21195148 | valproic acid | increases expression | ISO | RGD:732054 | 6480464 | Valproic Acid results in increased expression of ADGRL2 mRNA | CTD | PMID:24383497 more ... | valproic acid | multiple interactions | ISO | RGD:732054 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | vorinostat | increases expression | ISO | RGD:732054 | 6480464 | vorinostat results in increased expression of ADGRL2 mRNA | CTD | PMID:27188386 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Welcome {{ username}}
Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{gene.symbol}}: {{ gene.description }}
|
| Save what matters to you |
| {{ loginError }} |
| Sign in with your RGD account |
| Create New Account | Recover Password |
Analyze GeneStrainQTL List |
 Gene Annotator (Functional Annotation) unavailable |
 Gene Annotator (Annotation Distribution) unavailable |
 Variant Visualizer (Genomic Variants) unavailble Variant Visualizer (Genomic Variants) unavailable |
Gene Annotator (Functional Annotation) |
Gene Annotator (Annotation Distribution) |
Variant Visualizer (Genomic Variants) |
 InterViewer (Protein-Protein Interactions) unavailable |
 Gviewer (Genome Viewer) unavailable |
 Variant Visualizer (Damaging Variants) unavailble Variant Visualizer (Damaging Variants) unavailable |
InterViewer (Protein-Protein Interactions) |
GViewer (Genome Viewer) |
Variant Visualizer (Damaging Variants) |
 Gene Annotator (Annotation Comparison) unavailable |
 OLGA (Gene List Generator) unavailable |
 |
Gene Annotator (Annotation Comparison) |
OLGA (Gene List Generator) |
Excel (Download) |
 MOET (Multi-Ontology Enrichement) unavailable |
 GOLF (Gene-Ortholog Location Finder) unavailable |
|
MOET (Multi-Ontology Enrichement) |
GOLF (Gene-Ortholog Location Finder) |
|
||||||||
Gene Ontology Annotations Click to see Annotation Detail View
Biological Process
Cellular Component
Molecular Function
Gene-Chemical Interaction Annotations
Click to see Annotation Detail View
Gene Ontology Annotations
Click to see Annotation Detail View
Biological Process
|
|
|
Cellular Component
|
|
|
Molecular Function
|
|
References
References - curated
| 1. | Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27. |
| 2. | GOA data from the GO Consortium |
| 3. | Ichtchenko K, etal., J Biol Chem 1999 Feb 26;274(9):5491-8. |
| 4. | Kreienkamp HJ, etal., J Biol Chem. 2000 Oct 20;275(42):32387-90. |
| 5. | MGD data from the GO Consortium |
| 6. | NCBI rat LocusLink and RefSeq merged data July 26, 2002 |
| 7. | RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations |
| 8. | RGD automated import pipeline for gene-chemical interactions |
| 9. | Tobaben S, etal., J Biol Chem 2000 Nov 17;275(46):36204-10. |
| 10. | Vezain M, etal., Acta Neuropathol Commun. 2018 Oct 19;6(1):109. doi: 10.1186/s40478-018-0610-5. |
Additional References at PubMed
| PMID:8889548 | PMID:9830014 | PMID:16641100 | PMID:23012479 | PMID:24613359 | PMID:28972101 |
Genomics
